Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma

This study has been terminated.
(closed to recruitment early due to AstraZeneca not developing cediranib further)
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
University College, London
ClinicalTrials.gov Identifier:
NCT01310855
First received: March 5, 2011
Last updated: July 3, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: January 2014
  Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)